Quarterly Sales (Approved)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: FIRDAPSE®(Amifampridine) for Lambert-Eaton myasthenic syndrome (LEMS) - Quarterly Sales (Approved)
WHAT IS THE NEXT CATALYST EVENT?
Updates on Patent Litigation
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-10-2020 2020 Third Quarter Financial Results
2016: Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53(5):717-725.
2014: Update on Amifampridine as a Drug of Choice in Lambert-Eaton Myasthenic Syndrome. US Neurology. 2014; 10(2): i-vii
2014: 3,4-Diaminopyridine (amifampridine) for the treatment of Lambert–Eaton myasthenic syndrome. Expert Opin Orph Drugs. 2014; 2(3):293-300.
MECHANISM OF ACTION
Firdapse® (amifampridine) 10 mg tablets is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization. This action results in the opening of slow voltage-dependent calcium (Ca2+) channels, allowing for a subsequent influx of Ca2+. In turn, it induces the exocytosis of synaptic vesicles containing Acetylcholine (ACh) to release more ACh into the synaptic cleft, enhancing neuromuscular transmission, and providing for improved muscle function.
Updated by JM
CPRX, Catalyst Pharma, Lambert-Eaton myasthenic syndrome (LEMS), Litigation, FIRDAPSE (Amifampridine)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post